New England Institute for Neurology and Headache

Recent papers from New England Institute for Neurology and Headache

1. Changes in medical students’ knowledge of medication-overuse headache after a dedicated educational courseThe Journal of Headache and Pain · 2026
2. Post Hoc Analysis of Time to First and Sustained Improvement in Weekly Migraine Days Among Patients Receiving Preventive Treatment With Rimegepant 75 mgPain and Therapy · 2026
3. Safety and tolerability of transnasal evaporative cooling for the acute treatment of migraine in an at‐home setting: A randomized, double‐blind, sham‐controlled, decentralized clinical trialHeadache The Journal of Head and Face Pain · 2026
4. Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trialThe Lancet Neurology · 2026
5. Efficacy and safety of eptinezumab in adults with chronic migraine and medication-overuse headache who also received patient education: 24-week results of the randomized RESOLUTION trialThe Journal of Headache and Pain · 2026
6. Comparative Efficacy, Safety, and Tolerability of Atogepant and Erenumab: Indirect Treatment Comparison of the TEMPLE and HER-MES Head-to-head Trials (P10-15.002)Neurology · 2026
7. Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Participants Requiring Preventive Treatment for Migraine: Results from the Head-to-head TEMPLE Trial (P10-15.009)Neurology · 2026
8. A retrospective cohort study comparing treatment persistence between rimegepant and lasmiditan for the acute treatment of migraine in the USCephalalgia · 2026
9. Benefits of eptinezumab on patient-reported disease burden and health-related quality of life in adults with chronic migraine and medication-overuse headache: Results from the placebo-controlled RESOLUTION trialCephalalgia · 2026
10. Integrated analysis of two randomized controlled trials of a digital therapeutic for episodic migraine preventionnpj Digital Medicine · 2026
11. Chronic Spontaneous Urticaria with Angioedema Refractory to Standard Therapy: Insights Into the Protean Nature of a Common PresentationSHILAP Revista de lepidopterología · 2026
12. Eptinezumab With Patient Education for Chronic Migraine and Medication-Overuse HeadacheNeurology · 2026
13. Diagnosis challenges and accessibility barriers to migraine management in Southeast Asia: results from the South-East Asia Local breAch on MigraiNe Treatment (SEALANT) studyThe Journal of Headache and Pain · 2026
14. DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia: Clinical Insights from a Real‐World Early Experience ProgramMovement Disorders Clinical Practice · 2026
15. Parenting-STAIR Modular: a randomized controlled trial of a trauma-focused parenting intervention for military-connected mothers and their childrenTrials · 2026
16. Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trialCephalalgia · 2025
17. Rimegepant for acute treatment of migraine in triptan-unsuitable adults: A randomized, double-blind, placebo-controlled phase 4 trialCephalalgia · 2025
18. International Headache society evidence-based guidelines on the use of non-invasive neuromodulation devices for the acute and preventive treatment of migraineThe Medicine Forum · 2025
19. Migraine in the workplace: Work productivity impact in a large US-based healthcare system using a cross-sectional employee survey.2025
20. State of the art in the management of migraine—A response to the American College of Physicians migraine preventive treatment guidelineHeadache The Journal of Head and Face Pain · 2025